Petros Pharmaceuticals Responds to Fraudulent Press Release
28. Juli 2022 10:27 ET
|
Petros Pharmaceuticals, Inc.
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today confirmed that a press release issued on July 28,...
Petros Pharmaceuticals Kicks Off Social Media Campaign with Celebrity Physician Dr. Drew Pinsky
19. Juli 2022 09:15 ET
|
Petros Pharmaceuticals, Inc.
NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces that it has signed a compensated...
Petros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
16. Mai 2022 17:00 ET
|
Petros Pharmaceuticals, Inc.
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today announced financial...
Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company’s Novel Topical Investigational Treatment for Peyronie’s Disease Which Impacts More Than 1 in 10 Men in the US
03. Mai 2022 09:23 ET
|
Petros Pharmaceuticals, Inc.
NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, announces today they will be pursuing the 505(b)(2)...
Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022
27. April 2022 21:25 ET
|
Petros Pharmaceuticals, Inc.
NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, announces today that President and Chief Commercial...
Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology
26. April 2022 09:15 ET
|
Petros Pharmaceuticals, Inc.
NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Petros, Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today announces it has entered into a Sponsored...
Petros Pharmaceuticals Announces Positive Results of Over-the-Counter (OTC) Label Comprehension Study for Erectile Dysfunction Drug STENDRA (avanafil)
19. April 2022 09:15 ET
|
Petros Pharmaceuticals, Inc.
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today provides positive...
Petros Pharmaceuticals to Present at the Q1 Investor Summit Conference
03. März 2022 08:00 ET
|
Petros Pharmaceuticals, Inc.
NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, announces today that President and Chief Commercial...
Petros Pharmaceuticals to Participate in NobleCon17
19. Januar 2021 08:00 ET
|
Petros Pharmaceuticals, Inc.
NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals (Nasdaq: PTPI) today announces that its president and chief commercial officer Fady Boctor will present at NobleCon17 - Noble...